Exscientia, the clinical stage, artificial intelligence-driven pharmatech company, has announced a significant expansion of its headquarters at The Oxford Science Park (TOSP), one of the UK’s leading parks for science and technology companies. The company, which initially occupied around 7,800 sq ft in TOSP’s prestigious Schrödinger Building, is now working from 21,000 sq ft of laboratory and office facilities. Having already created over 100 new jobs so far this year, the company expects to add a similar number of new roles in the Oxford area over the next year. Exscientia also has facilities in Scotland, Japan and the USA.
The headquarters expansion at TOSP provides increased space for Exscientia’s technology teams and laboratory capabilities in structural biology, biophysics and pharmacology. The company now has 25 active research programmes, both in-house and with partners. It has developed significantly this year, having completed fundraising rounds in excess of $300m, and signed several partnership deals.
Rory Maw, Bursar of Magdalen College & Interim MD of TOSP, said: “Exscientia is a leading player in AI-driven drug discovery, and we are delighted that it has expanded its headquarters so significantly here since 2018. The resultant job creation in the local economy is very welcome. TOSP looks forward to continuing to support the growth of Exscientia, which is an important member of our AI cohort here alongside companies such as Etcembly, MoA Technology and Sensyne Health.”
The Oxford Science Park is owned and managed by Magdalen College, Oxford. Created in 1991, the Park upholds the College’s heritage and provides one of the most influential science & technology environments in the UK. There is approaching 750,000 square feet of workspace accommodation across the Park, which is now home to 2,700 people and more than 130 businesses. These range from start-ups based in the Magdalen Centre innovation hub to major international companies and include Blue Earth Diagnostics, MiroBio, OrganOx, OxSonics Therapeutics, Oxford Nanopore Technologies, OXGENE, ProImmune, Oxford Sciences Innovation, Evox Therapeutics, Vaccitech, Exscientia, Sensyne Health and Intuitive Surgical.